Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Marizyme Inc (QB) | MRZM | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.093 | 15:03:40 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.093 | 0.093 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.05 - 0.405 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.093 | USD |
Marizyme Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.2M | 43.42M | 12.02M | 646k | -65.35M | -1.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marizyme (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/28/2024 | 15:23 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/15/2024 | 15:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 5/13/2024 | 15:50 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 5/06/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/06/2024 | 15:15 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/06/2024 | 07:55 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/29/2023 | 16:15 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/28/2023 | 19:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/28/2023 | 05:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/22/2023 | 15:36 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/21/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/16/2023 | 05:08 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRZM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.093 | 0.093 | 0.093 | 0.093 | 5,000 | 0.00 | 0.00% |
| 1 Month | 0.09 | 0.093 | 0.0533 | 0.0902201 | 3,950 | 0.003 | 3.33% |
| 3 Months | 0.095 | 0.095 | 0.053 | 0.0797016 | 5,691 | -0.002 | -2.11% |
| 6 Months | 0.14 | 0.15 | 0.053 | 0.094198 | 7,692 | -0.047 | -33.57% |
| 1 Year | 0.28255 | 0.405 | 0.05 | 0.1689108 | 16,334 | -0.18955 | -67.09% |
| 3 Years | 1.50 | 3.25 | 0.05 | 0.5803531 | 8,145 | -1.41 | -93.80% |
| 5 Years | 0.5513 | 4.48 | 0.05 | 0.7640472 | 5,534 | -0.4583 | -83.13% |
Marizyme (QB) Description
| Marizyme is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes. Currently, we are focused on developing three medical technology products -- DuraGraft, MATLOCTM and Krillase -- each of which is backed by a portfolio of patented or patent-pending assets. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, therefore maintaining endothelial function and structure while improving clinical outcomes. MATLOC is a point-of-care, lab-on-chip digital screening and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment. Our Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health. |
